Clarity Medical Group Holding Limited announced that Ms. Cheng Jessica has been appointed as an independent non-executive Director with effect from 29 May 2024. Ms. Cheng, aged 43, has over 17 years in the medical industry. Ms. Cheng is currently a managing partner of Chief Sound Industries Limited, an electronics manufacturing company in the People's Republic of China (the ``PRC''); a consultant at Genesis Medical Technology (Shanghai) Company Limited, an international medical device company; and an advisory partner at MCM Partners, a global merchant bank, corporate advisor and asset management firm headquartered in Hong Kong.

Previously, Ms. Cheng held the position of President of the Greater Bay Area at Genesis GBA Limited, an international medical device company from 2021 to 2023. Ms. Cheng also served as an independent consultant to BGI Health (HK) Company Limited, a subsidiary of BGI Genomics. Between 2018 and 2020, Ms. Cheng served as the chief operating officer in the Greater Bay Area and chief operating officer for the Strategic Investment Department at WeDoctor (Hong Kong) Limited, a technology-enabled healthcare solutions platform in the PRC.

Prior to the above, Ms. Cheng worked in both commercial firms and government statutory bodies in the medical sector, including serving as the manager of the chairman and chief executive's office of the Hong Kong Hospital Authority from 2009 to 2014. Ms. Cheng obtained a Bachelor of Business Administration degree from the University of Kent (formally known as the University of Kent at Canterbury), United Kingdom, in 2001, and a Master of Science degree in Training and Human Resource Management from the University of Leicester, United Kingdom, in 2010. Following the appointment of Ms. Cheng as an independent non-executive Director, the Board comprises three executive Directors, three non-executive Directors and three independent non-executive Directors.

As a result, the Company complies with the requirements under Rules 3.10(1), 3.10A and 3.21 of the Listing Rules in respect of the minimum number of independent non-executive Directors and the minimum number of members of the Audit Committee.